Pre-Conference: March 28, 2014
Main Conference: March 29–30, 2014
Chronic Liver Disease 2014 (PDF, 481 KB)
We will review the virology, genotypes, modes of infection of HCV and characteristics of the clinical illness caused by acute and chronic infections. Tests for HCV, including PCR assays and genotyping, interpretations and indications for liver biopsies and complications of cirrhosis will all be discussed. We will show how to initiate and monitor patients during treatment with telaprevir and boceprevir, manage of side effects of rash and hematologic complications of therapy and deal with various patient populations including African Americans, HIV-coinfected and ESLD patients. Lastly, new drugs in development including protease inhibitors, nucleoside and non-nucleoside polymerase inhibitors, NS5A inhibitors, and other novel agents will be discussed.
This CME conference will review new medications and therapies that are now available, or will soon be available, and discuss their comparative values. The results of trials using new drugs to treat chronic viral hepatitis B and C, non-alcoholic fatty liver diseases, cholangiocarcinoma, primary biliary cirrhosis, primary sclerosing cholangitis, hepatocellular carcinoma and complications of end-stage liver disease will be reviewed in detail. New Treatments in Chronic Liver Disease is a comprehensive yet concise program for updating physicians on these and other commonly encountered problems in the treatment of liver diseases.
There was a fundamental change in the treatment of chronic hepatitis C in 2014 with the addition of 2 new direct-acting antiviral (DAAs) drugs to current standard of care for all genotypes. There will be two separate lectures devoted to this topic this year. The first will be on triple therapies that were approved in late 2013. The second will be on future therapies using two or more DAA’s without interferons.
We anticipate that there will be a number of new demands placed on treatment providers, including screening, access to treatment, costs of therapy and the continuation of complex algorithms for interferon-based regimens. Looking beyond 2014, we see numerous combinations of DAA’s in development including protease inhibitors, nucleoside polymerase inhibitors, non-nucleoside polymerase inhibitors and N55A inhibitors. All of these agents are in phase 3 development and a number have completed studies and are awaiting FDA review. In hepatitis B, the treatments have not changed but there is more mature data available on renal resistance, long-term HBsAg loss and clinical outcomes. The addition of hepatitis E as an important disease and a treatable form of viral hepatitis has been included in this year’s program. New therapies for NAFLD and NASH are in development and will be explored. The explosive growth of NASH in the US has created a significant need for effective drug therapy. The diagnosis and treatment of hepatocellular carcinoma will be updated as this disease is one of the few cancers with a growing incidence in the US. New oral therapy is moving this field forward. There will be an update on management of hepatic encephalopathy, hyponatremia and the management of pulmonary complications in the transplant candidate.
- Half Day Pre-Conference Seminar reviewing the virology, genotypes and modes of infection of HCV. Participants will learn the details of new AASLD guidelines for treatment of HCV using DAA’s in combination with pegylated interferon and ribavirin.
- Comprehensive presentations of the latest advances in hepatology with renowned faculty chosen for their expertise as well as teaching skills.
- Endorsed by the American College of Gastroenterology
- Attendees will have opportunities to network with each other and interact with speakers to discuss topics from the course.
New for 2014
Conference presentations (pre and main conference) will be available via mobile app and conference website. You are able to download, save and/or print these presentations from the mobile app and conference website onto your tablet, laptop or smart phone. Attendees will receive an email prior to the conference with directions on how to access the mobile app and conference website and how to download the presentations. You will also want to bring your tablet, laptop or smart phone with you to the conference. Internet will be available in the meeting space.
- Infectious Disease Specialists
- Nurse Practitioners
- Physician Assistants
- and others desiring an update in these specialty areas
- Hilton La Jolla Torrey Pines
- 10950 North Torrey Pines Road
- La Jolla, CA 92037 US 32.9018 -117.244
|Friday, March 28th, 2014 - Sunday, March 30th, 2014||8:00 am - 11:45 am|